Frequency Doubling Technology (FDT) Mobile Visual Field Testing

Sponsor
University of Miami (Other)
Overall Status
Recruiting
CT.gov ID
NCT02862158
Collaborator
(none)
500
1
1
75
6.7

Study Details

Study Description

Brief Summary

This is a single center, prospective study to evaluate the efficacy and reproducibility of frequency doubling technology (FDT)-based visual field devices compared to conventional Humphrey Visual Field (HVF) perimetry. The investigators plan to enroll 500 patients in this study.

Condition or Disease Intervention/Treatment Phase
  • Device: FDT visual field
  • Device: Standard HVF
N/A

Detailed Description

Glaucoma is a leading cause of irreversible and preventable blindness world-wide. Insufficient evidence exists to support routine screening for glaucoma in a primary care setting due to the relatively low prevalence of the disease (Guirguis-Blake, 2005 and Moyer, 2013). Frequency doubling technology (FDT)-based perimetry is a relatively inexpensive and portable visual field testing device with a short testing time that has shown reasonable efficacy, sensitivity and specificity in screening for glaucoma in clinic- and community-based settings (Mansberger, 2005 and Nomoto 2009).

The aim of our study is to compare the efficacy and reproducibility of FDT perimetry platforms compared with Humphrey Visual Field (HVF) perimetry (which is the gold clinical standard in clinics and hospitals) in detecting glaucomatous visual field defects.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
500 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Evaluation of Different Frequency Doubling Technology (FDT) Mobile Devices for Visual Field Assessment
Study Start Date :
Aug 1, 2016
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Nov 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental

FDT visual field will be compared to standard HVF in detecting glaucomatous visual field loss

Device: FDT visual field

Device: Standard HVF

Outcome Measures

Primary Outcome Measures

  1. Pattern of visual field loss in FDT visual fields as compared with standard HVF [The investigators anticipate to enroll the subjects over a period of 12 months. The estimated time required for data analysis is 6 months following enrollment of all subjects.]

    Visual Field

Secondary Outcome Measures

  1. Mean deviation (MD) in FDT visual fields as compared with standard HVF [The investigators anticipate to enroll the subjects over a period of 12 months. The estimated time required for data analysis is 6 months following enrollment of all subjects.]

    Visual Field

  2. Pattern standard deviation (PSD) in FDT visual fields as compared with standard HVF [The investigators anticipate to enroll the subjects over a period of 12 months. The estimated time required for data analysis is 6 months following enrollment of all subjects.]

    Visual Field

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult patients (18 and over) who speak English, Spanish or Creole, and are capable of providing informed consent and who have a Humphrey Visual Field (HVF) test within the prior the 6 months preceding enrollment are eligible for enrollment in this non-invasive study. Patients will be recruited from among patients at the Bascom Palmer Eye Institute clinics during their regularly scheduled clinic visits. No advertising will be used to recruit patients.
Exclusion Criteria:
  • Adults unable to consent, individuals who are not yet adults (infants, children and teenagers), pregnant women and prisoners and other vulnerable populations will be excluded from the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Bascom Palmer Eye Institute, University of Miami Miller School of Medicine Miami Florida United States 33136

Sponsors and Collaborators

  • University of Miami

Investigators

  • Principal Investigator: Richard Lee, MD, PhD, University of Miami / Bascom Palmer Eye Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Richard K. Lee, Associate Professor of Ophthalmology, Cell Biology and Neuroscience Graduate Program, University of Miami
ClinicalTrials.gov Identifier:
NCT02862158
Other Study ID Numbers:
  • 20150968
First Posted:
Aug 10, 2016
Last Update Posted:
Oct 30, 2020
Last Verified:
Oct 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 30, 2020